Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CirQuest Labs, LLC
With
Janssen Scientific Affairs, LLC
This is a cross-sectional, single center exploratory study of plasma biomarker levels in adults with decompensated heart failure and significant underlying coronary artery disease as compared with age-matched healthy controls. Subjects will not receive a therapeutic treatment as part of this study and will undergo a single blood draw.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Group 1: Heart Failure with Coronary Artery Disease Subjects
Symptomatic heart failure (≥ 3 months) with most recently documented LVEF ≤ 40% (Echo must have been completed in last 12 months prior to enrollment.)
Significant underlying coronary artery disease as evidenced by:
previous myocardial infarction
prior coronary artery bypass graft
50% coronary stenosis of one or more arteries and/or
history of percutaneous coronary intervention with or without stenting
Age 18 years or older at the first screening visit
Group 2: Healthy Subjects
Age 18 years or older at the first screening visit and within 20% of mean age of Group 1 Subjects
You may not be if
Group 1:
Documented history of "severe" valvular disease
Documented history of atrial fibrillation, ventricular fibrillation or ventricular tachycardia.
Recent or current use of anticoagulant medications such as fXa inhibitors, direct thrombin inhibitors, vitamin K antagonists, or heparin. (within 1 month of screening)
Group 2:
Known significant cardiovascular or hematological condition
Recent or current use of anticoagulant medications such as fXa inhibitors, direct thrombin inhibitors, vitamin K antagonists, or heparin. (within 1 month of screening)
Recent cold or flu symptoms, respiratory infection or surgery (within 2 weeks of screening)
